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Abstract  
Purpose: Cancer-related cognitive impairment (CRCI) is a common, fatigue-related symptom that 
disrupts cancer survivors’ quality of life. Few interventions for CRCI exist. As part of a randomized pilot 
study targeting cancer-related fatigue, the effects of Mindfulness-Based Stress Reduction (MBSR) on 
survivors’ cognitive outcomes were investigated.  
Methods: Breast and colorectal cancer survivors (n=71) with moderate-to-severe fatigue were randomized 
to MBSR (n=35) or a fatigue education and support (ES; n=36) condition. The Attentional Function Index 
(AFI) and the Stroop test were used to assess survivors’ cognitive function at baseline (T1), after the 8-
week intervention period (T2), and 6 months later (T3) using intent-to-treat analysis. Mediation analyses 
were performed to explore mechanisms of intervention effects on cognitive functioning. 
Results: MBSR participants reported significantly greater improvement on the AFI total score compared 
to ES participants at T2 (d= 0.83, p = 0.001) and T3 (d = 0.55, p = 0.021).  MBSR also significantly 
outperformed ES on most AFI subscales, although both groups improved over time. MBSR produced 
greater Stroop accuracy rates relative to ES at T2 (r = 0.340, p = 0.005) and T3 (r = 0.280, p = 0.030), 
with improved accuracy over time only for the MBSR group. There were no significant differences in 
Stroop reaction time between groups. Improvements in mindfulness mediated the effect of group (e.g., 
MBSR vs. ES) on AFI total score at T2 and T3.    
Conclusions:  Additional randomized trials with more comprehensive cognitive measures are warranted 
to definitively assess the efficacy of MBSR for CRCI.    
Implications for Cancer Survivors: This pilot study has important implications for all cancer survivors as 
it is the first published trial to show that MBSR offers robust and durable improvements in CRCI.   
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Introduction 
Cancer-related cognitive impairment (CRCI) is a prevalent and disruptive symptom [1], affecting 
15-75% of patients with breast and colorectal cancer [2-4]. Attention, memory, and executive function 
often are compromised [5-6].  Cognitive impairment has been associated with higher levels of depressive 
symptoms, anxiety, and fatigue [7-8], which are the most common symptoms reported among cancer 
survivors post-treatment [8].  Cognitive deficits can persist up to 20 years post-treatment [9]. Without 
supportive treatment, persistent cognitive impairment can negatively affect cancer survivors’ self-
confidence [10], social relationships [10-11], work ability [10,12], and quality of life [10,13].  
Despite CRCI’s prevalence, few interventions targeting this symptom have been evaluated [14]. 
A number of interventional studies have shown promise in reducing the stress associated with CRCI [12]; 
however, few have directly addressed CRCI itself. An integrative therapeutic intervention that has 
become increasingly popular and that may hold promise in relieving CRCI is Mindfulness-Based Stress 
Reduction (MBSR) [15]. Through a variety of guided, experiential mindfulness meditation practices, 
individuals in an MBSR course learn to focus their attention on present-moment experience with an 
attitude of curiosity, openness, and acceptance. Mindfulness training is thought to improve cognitive 
functioning through mechanisms of focused attention (e.g., directing and sustaining attention on a 
selected object, such as one’s breath, while noticing and disengaging from distractions and mind 
wandering) and open monitoring (e.g., non-reactive meta-cognitive attending to experience, including 
automatic cognitive and emotional interpretation of stimuli) [16]. Through the attentional control 
mechanisms of mindfulness [17-18], cognitive deficits in attention, memory, and executive function 
among cancer survivors could be alleviated.  
Empirical evidence has emerged that suggests mindfulness may lead to improved cognitive 
function. A recent systematic review found mindfulness meditation improved working memory as well as 
sustained and selective attention in non-cancer populations with no prior meditation experience [19]. 
Although MBSR has shown efficacy in reducing a range of cancer-related symptoms such as depression, 
anxiety, and fatigue, [20-23], studies are lacking regarding its impact on CRCI [24]. In the largest 
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randomized MBSR trial for post-treatment breast cancer survivors to date (n=229), Hoffman and 
colleagues [20] investigated the effects of MBSR on mood compared to a wait-list control group. They 
noted significant post-intervention improvement on the confusion subscale of the Profile of Moods States 
(POMS) favoring the MBSR group. However, the between-group difference was no longer significant at 
12 weeks. Another randomized trial comparing MBSR to wait-list control among a heterogeneous sample 
of cancer outpatients similarly found short-term benefits of MBSR in reducing confusion on the POMS 
[25]; however, at 6-month follow up, between-group differences were not found [26]. Despite these 
promising findings in cancer survivors, as well as direct evidence that MBSR improves cognitive function 
in healthy samples [19], no randomized trial has examined the effects of MBSR on CRCI. 
The purpose of the current study was to examine the impact of an 8-week MSBR program 
compared to an 8-week fatigue education and support (ES) intervention on subjectively and objectively 
assessed cognitive function among cancer survivors with fatigue. Potential mechanisms of intervention 
effects on subjective and objective cognitive functioning also were explored. We hypothesized that 
MBSR would be superior to ES in improving cognitive outcomes for cancer survivors and that 
mindfulness would mediate the relationship between intervention and cognitive outcomes. Notably, the 
results reported here reflect a secondary analysis of a trial testing the efficacy of MBSR on cancer-related 
fatigue (CRF), and these results have been presented elsewhere [27]. Given that the nature of the 
relationship between CRF and CRCI is unknown, the findings of this study only apply to post-treatment 
cancer survivors with fatigue. 
Methods 
Design 
This pilot study was a 2-arm randomized clinical trial. Institutional Review Boards at Indiana 
University and Community Health Network approved study procedures. Written informed consent was 
obtained from all participants. The study is registered with ClinicalTrials.gov (NCT01919853).  
Participants 
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Over a 5-month period in 2012-2013, consecutive breast (n=60) and colorectal (n=11) cancer 
survivors (BCS and CRCS, respectively) with CRF were recruited. BCS and CRCS were included 
because these are two of the most common cancers with a sizeable number of patients experiencing 
fatigue after treatment with curative intent [28]. Survivors were identified at a midwestern National 
Cancer Institute-designated cancer center and its affiliated oncology clinics, as well as through a tumor 
registry and community cancer clinic. Potential participants were informed of the study’s purpose, and 
interested individuals were assessed for eligibility.  
Participants were eligible for the study if they were at least 18 years of age, had a first-time 
diagnosis of stage 0-III breast or colorectal cancer that had been treated with chemotherapy and/or 
radiotherapy, and had clinically significant CRF (Fatigue Symptom Inventory severity composite score 
≥4 [29]) that had persisted for at least 8 weeks. Excluded were those who had received chemotherapy, 
radiation therapy, or surgery less than 3 months or more than 5 years prior to enrollment; reported severe 
depressive symptoms (Patient Health Questionnaire-8 score ≥20 [30]); or reported previous participation 
in a mindfulness class and/or ongoing meditation practice. Eligibility was not based upon the presence of 
CRCI, but upon CRF, a symptom often associated with cognitive impairment. 
Study procedures 
Eligible participants were invited to attend one of several group enrollment sessions, which 
included informed consent, collection of self-reported socio-demographic and medical characteristics, 
completion of baseline surveys, and randomization in a 1:1 ratio to MBSR or ES. The allocation sequence 
was generated by coin toss in randomly varied block sizes of 4 or 6 by the principal investigator. The 
allocation sequence was concealed from participants and research assistants through the use of opaque 
and sequentially numbered envelopes. Participants were blinded to study hypotheses and to the content of 
the course to which they were not assigned. Once participants were randomized, they met with a 
facilitator of their assigned intervention for a brief orientation. During orientation, participants assigned to 
the ES group were asked to not participate in mindfulness training during the study. The 8-week group 
interventions began the following week.  
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Interventions 
The MBSR and ES interventions each consisted of 8 weekly 2-hour classes led by skilled 
facilitators following standardized procedures. Each group was limited to approximately 10 participants 
to encourage group cohesion and ensure that each group received equal amounts of facilitator attention 
and time for group discussion and interaction. MBSR and ES classes were held on the same day and time; 
however, care was taken to keep the MBSR and ES participants in separate locations to limit 
contamination. MBSR and ES facilitators contacted participants who missed a class by phone or email, 
and if the participant was willing and able, highlights of the missed class were covered and class materials 
were sent. Fidelity to MBSR and ES was ensured through the use of standardized manuals, and sessions 
were audio recorded. External reviewers used checklists created for each intervention condition to 
evaluate 25% of randomly selected sessions for each intervention condition to ensure adherence to the 
protocol.   
MBSR training included instruction on formal mindfulness meditation practices including body 
scan, mindful movement featuring hatha yoga poses, sitting meditation, and lovingkindness; and 
incorporated informal practices to cultivate present-moment awareness in everyday life. The goal of these 
practices is to facilitate adaptive, non-reactive, and nonjudgmental relating to thoughts, feelings, and 
bodily sensations by enhancing awareness of the present moment. Classes also included didactic 
instruction that covered all the MBSR standard curriculum topics, and interactive group discussion of the 
development and integration of mindfulness-based self-regulatory skills in daily life. MBSR facilitators 
were a physician and a doctoral-level clinical health psychologist with 9 and 3 years of MBSR teaching 
experience, respectively.  Each had completed the professional training leading to eligibility for MBSR 
Teacher Certification Review through the Center for Mindfulness at the University of Massachusetts.  
Meditation guidance was provided in the weekly classes and through audio recordings outside of 
class consistent with standard MBSR curriculum [31]. To make the training more feasible for fatigued 
cancer survivors, classes were 2 hours instead of the MBSR standard of 2.5 hours due to slight decreases 
in length of in-session meditation practices. The standard all-day retreat was not included, and formal 
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home meditation practices were 20 minutes instead of the MBSR standard of 45 minutes. Participants 
used logs to track the type and amount of formal meditation practices completed daily. 
ES sessions were led by masters-level oncology social workers and included a hybrid of didactic 
teaching and opportunities to share experiences living with cancer-related symptoms. Class topics, which 
varied each week, focused on fatigue and challenges faced during survivorship  (e.g., lingering and late 
effects of cancer treatment, impact of fatigue on relationships), strategies for symptom self-management 
(e.g., sleep hygiene, coping with distress),  eating to maximize energy, increasing physical activity, and 
survivorship care planning. For between-session home practice, participants were provided weekly 
readings that supplemented course content. Participants were invited to log the amount of time they spent 
doing reading assignments and other self-care strategies discussed in class on weekly home practice logs. 
At the end of the study, participants were provided with information on how to access MBSR classes. 
Measures 
Cognitive function and mindfulness were evaluated at baseline (T1), after the 8-week intervention 
period (T2), and 6 months post-intervention (T3). The study used both subjective and objective measures 
of cognitive function, as recommended in a recent systematic review; despite the documented discrepancy 
between objectively confirmed impairment and perceived impairment, measures of each type yield 
relevant information about the cognitive functioning of cancer survivors [32].  The data were collected by 
research assistants blinded to participants’ intervention group. Participants received $25 at each 
assessment period as an incentive for completing the following measures. 
Subjective measure. The Attentional Function Index (AFI) is a 13-item, self-report measure that 
assesses perceived effectiveness in common activities requiring attention and working memory (e.g., 
formulating plans, carrying out tasks, making decisions, keeping a train of thought, and attending to what 
others are saying) [33]. Each item of the AFI was evaluated using a linear analog scale, consisting of a 
100 mm horizontal line anchored with opposite phrases from “not at all” (0 mm) to “extremely well or a 
great deal” (100 mm). Respondents were asked to place a mark through the horizontal line to indicate 
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how well they were functioning at the time. Scores for each item were determined by measuring the 
distance in millimeters from the lower end of the scale to a participant’s indicated mark along the line. 
Measurements were made by two research assistants, and discrepancies were discussed until consensus 
was reached. Total score was calculated as the average of the 13 items. Mean scores also were calculated 
for each of the AFI’s three subscales: effective action (7 items), attentional lapses (3 items), and 
interpersonal effectiveness (3 items). Higher mean scores indicate greater capacity to direct attention. The 
AFI has well-established reliability and has been validated in cancer populations [33]. For the present 
study, Cronbach’s alpha for AFI total at T1 was 0.87. Participants completed the AFI on paper at the 
study site, with the exception of three participants who did not complete their assigned intervention. 
These participants continued completing the study measures at home, either on paper or online, as part of 
the intent-to-treat design. 
Objective measure. The Stroop color-word test [34] is a test of  executive attentional functioning, 
including selective attention and cognitive flexibility and control [35]. The Stroop test was administered 
via a laptop computer.  Participants were presented with a fixation cross (‘+’) for 500 ms, followed by a 
color word—BLUE, GREEN, ORANGE, or PURPLE—in either congruent or incongruent script color. 
After each word presentation, participants were instructed to identify the actual script color by pressing a 
corresponding key on the laptop keyboard as quickly as possible, while ignoring the habitual process of 
word reading. Several practice trials were allowed prior to testing to ensure that participants understood 
the instructions. Participants then completed two randomized blocks of 40 experimental trials, one block 
consisting of congruent trials and one consisting of incongruent trials. Accuracy (error) rate and average 
reaction time (RT) for each block were recorded. 
The Stroop test is widely used in psychological and medical research because of its flexibility. 
Multiple parameters (e.g., color, order, speed, mode of administration) can be varied to tailor the test to 
the sample of interest. Participants in this study were suffering with CRF, and therefore the Stroop test 
was modified, using a relatively small number of words and blocks, to minimize its burden. 
Unfortunately, norms for the Stroop test are rarely available in research contexts precisely because of the 
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test’s flexibility. Yet, the Stroop test has been used extensively for decades across multiple disciplines 
because, despite the many ways it can be administered, it produces valid and reliable results.  
Mindfulness. The 39-item Five Facet Mindfulness Questionnaire [36] was used to evaluate the 
tendency to be mindful in daily life. Participants rated the extent to which they were mindful on a 5-point 
Likert scale (1=never or very rarely true; 5=very often or always true), with higher scores representing 
greater mindfulness. Mean scores were calculated for each of the measure’s 5 subscales including 
observing, describing, acting with awareness, non-judgment of inner experience, and non-reactivity to 
inner experience. Validity and internal consistency for the FFMQ are good [36-37]. 
Attendance and home practice. Study interventionists tracked attendance of each participant at 
each session. Participants were asked to track the type and amount of meditation practice (MBSR group) 
and the number of minutes spent completing reading assignments and using self-care strategies (ES 
group) between sessions on logs they placed in a sealed envelope each week during the intervention 
period. These logs were not seen by the study interventionists. At the 6-month follow-up, MBSR 
participants were asked how many days per week, on average, they had participated in formal 
mindfulness practice (i.e., body scan, yoga, sitting meditation) since completing the MBSR class. A 
similar item asking about continued informal mindfulness practice (doing everyday activities mindfully) 
was also included.       
Statistical Analysis 
 Intent-to-treat analyses were conducted. All participants and their available data were included in 
the analyses according to participants’ randomly assigned group membership regardless of attendance or 
engagement in the intervention. Imputation was used to fill in missing data. When computing scale 
scores, a person-specific and scale-specific mean of non-missing items was substituted for missing items 
if 33% or fewer of the scale’s items were missing. Groups were compared on demographic and medical 
characteristics and symptom reports (i.e., fatigue, depression, anxiety, sleep disturbance, pain) at T1 using 
Chi square and Fisher’s Exact test for categorical variables and t-tests for continuous variables (Table 1). 
Although there were no statistically significant differences between groups on these variables at p<0.05, 
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we controlled for characteristics thought to be clinically/theoretically relevant [38] in an investigation of 
CRCI and/or those where the between-group difference was p<0.10. Thus, we used age, education, 
income, and cancer type as covariates in all multivariable models to minimize potential confounding.  
Analysis of covariance (ANCOVA) was used to test efficacy by comparing MBSR to ES on AFI 
outcomes at T2 and separately at T3, while adjusting for covariates and baseline scale scores for each 
variable.  With a sample size that was powered as a pilot study, there were limits to the number of 
covariates that could be added to the model without destabilizing the model. A linear model should have 
at least 10 persons per parameter, where the intercept also counts as a parameter; thus, a sample size of 71 
should contain no more than 6 one-degree-of-freedom covariates, otherwise inflated standard errors could 
occur. The 6 independent variables in the current model included age, education, income, cancer type, 
intervention group, and baseline AFI. The symptom scores were not used as covariates because, with the 
exception of pain, they were significantly correlated with the baseline AFI total score (Table 2). As there 
were no significant group differences in baseline symptom scores (Table 1), it is unlikely that these scores 
could confound the intervention effects on AFI at T2 and T3. Effect sizes (Cohen’s d) for each AFI 
outcome variable were calculated as the standardized mean difference between the MBSR and ES groups 
at T2 and T3, divided by the pooled baseline standard deviation of the particular outcome variable.  
The paired t-test was used to assess within-group improvements on all AFI outcomes for each 
group at T2 and T3 as compared to T1 scores on each variable. Effect sizes (standardized response mean; 
SRM) were calculated for each AFI within-group test as the within-group difference between means (T1 
to T2; or T1 to T3) divided by the standard deviation (SD) of change scores. Two-sided 95% confidence 
intervals were computed for effect sizes.  
Because of technology issues and participant drop out, Stroop data could not always be collected 
from all participants. Stroop group means are based on available data, resulting in different sample sizes 
across the three time points.  In keeping with prior work [39-40], reaction times from the Stroop task were 
trimmed and transformed.  At each time point, reaction times exceeding 2.5 SDs were recoded as the 
mean latency plus 2.5 SDs for that time point. Because RT scores tend to be positively skewed, scores 
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were then log-transformed at each time point. Stroop interference scores for RT data, which reflect the 
extent to which participants experience difficulty inhibiting prepotent responses, an indicator of executive 
attentional function [35], were computed by subtracting congruent (i.e., control) trial means from 
incongruent trial means for each participant. This commonly used approach controls for base rate RT 
[39,41], which is a particular concern when using fatigued participants. A similar approach was used for 
Stroop accuracy (i.e., error) rates, which were computed by subtracting the congruent (i.e., control) trial 
accuracy rate from the incongruent trial accuracy rate for each participant. Accuracy rate data from the 
Stroop test were compared between groups at T2 and T3 using the two-sided Wilcoxon Rank Sum Test 
and within groups across time points using the two-sided Wilcoxon Signed Rank Test because the Stroop 
variable was highly skewed even after transformation. Effect size, r, was computed by dividing the z 
obtained from the Wilcoxon Rank tests by the square root of the total sample size. 
Mediational Analysis. To provide insight into how MBSR benefitted participants’ cognitive 
function, we examined whether changes on each of the five subscales of the FFMQ mediated the effect of 
group (i.e., MBSR vs. ES) on AFI total scores and on Stroop accuracy rates at T2 and T3.  For each 
mediator, indirect effects and the 95% confidence interval were computed for each of 10,000 
bootstrapped samples [42]. We examined each potential mediator separately because the FFMQ subscales 
are considered to be independent from a theoretical perspective, an assumption borne out by the low 
correlations we found among the changes on each subscale at each time point (all r’s < .46).    
Results 
Enrollment and Attrition 
Of the 224 consecutive survivors screened for eligibility, 153 were excluded (see Figure 1).  Of 
the eligible survivors, 49.0% (n=71) were enrolled and randomized. Retention rates for both groups were 
high at T2 (MBSR=97.1%; ES=97.2%) and at T3 (MBSR=94.3%; ES=97.2%). Two individuals dropped 
out between T1 and T2 due to lack of interest (one from each group), and one individual completed the 
MBSR intervention and T2 assessment, but was lost to follow-up at T3. Notably, four participants 
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(MBSR=3; ES=1) were unable to attend any of their respective intervention sessions, yet they continued 
to complete all study measures in keeping with intent-to-treat analysis. 
Baseline Participant Characteristics 
As reported in Table 1, the sample was predominantly white (70.4%) and female (90.1%), and a 
little more than half did not have a college degree (56.3%). About half were employed (52.1%), 
married/partnered (54.9%), and reported having a “comfortable” income (52.1%). Average time since 
completion of cancer treatment was approximately 2.4 years. At the time of enrollment, 46% of breast 
cancer survivors were on endocrine therapy.  
Attendance and Home Practice 
Attendance was similar between groups, with MBSR participants attending 5.8 sessions (SD = 
2.1) compared to 6.3 sessions (SD = 1.9) for ES participants [t(68)=0.96, p=0.30]. Although the 
difference was not statistically significant, MBSR participants reported more minutes per week on 
average completing meditation practice assignments at home [117.6 (SD = 85.9)] compared to ES 
participants’ time completing reading assignments or using self-care strategies discussed in class [92.5 
(SD = 92.1); t(69)=1.19, p=0.24]. Notably, at the 6-month follow-up, 75.8% of MBSR participants 
reported continued formal mindfulness practice such as body scan, sitting meditation, and yoga; however, 
the majority of these (63.6%) reported formal practice only once or twice per week. Most MBSR 
participants (84.8%) reported continued informal mindfulness practice at the 6-month follow-up. 
AFI  
Between-Group Effects. As shown in Table 3, the mean scores of the AFI total as well as the 
Effective Action and Attentional Lapses subscales were significantly and substantially higher in the 
MBSR group than in the ES group at the end of the intervention (T2; p≤0.004). Importantly, the improved 
MBSR scores remained stable, and the differences between groups continued to be significant six months 
later at T3 (p<0.027). Effect sizes accompanying the significant differences were moderate to large, 
ranging from 0.55 to 0.90. Scores on the AFI Interpersonal Effectiveness subscale, although favoring the 
MBSR group, were not significantly different between groups at any time point. Notably, the MBSR 
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group’s mean scores on the AFI total rose to approximately 65 at T2 and T3, indicating that participants 
rose from low to moderate cognitive functioning based on the instrument’s reported threshold scores. In 
addition, AFI Attentional Lapses and Interpersonal Effectiveness rose to just above a score of 65, which 
was the mean AFI score reported by Cimprich and colleagues in a large validation sample of breast 
cancer survivors [33].  In contrast, the ES group’s mean scores remained below 65 at every time point on 
all AFI outcomes.  
Within-Group Effects.  Both groups experienced statistically significant improvements in 
cognitive function over time, with effect sizes ranging from 0.40 to 0.96; however, MBSR participants 
tended to experience larger gains (Table 4).  Specifically, the MBSR group exhibited significant 
improvements at T2 on all AFI subscales, and these improvements were durable, with mean scores 
remaining stable from T2 to T3. In contrast, by T2, the ES group had improved on only the AFI total and 
Interpersonal Effectiveness subscale, although gains on the Effective Action subscale approached 
significance. However, the ES group showed significant improvements on all subscales by T3. Unlike the 
MBSR group, the ES group continued to show some improvement in cognitive function at T3, although 
these gains were not sufficient to raise ES participants to the same levels experienced by MBSR 
participants.   
Stroop Test 
 Between-group effects. No differences emerged between MBSR and ES participants at T2 or T3 
(all p>0.64) on Stroop interference scores. Table 5 shows the between-group effects on the Stroop test for 
accuracy rates. Compared to the ES group, the MBSR group made fewer errors on the incongruent trials 
relative to errors on the congruent trials at T2 and T3. The groups did not differ at T1, suggesting the 
differences at T2 and T3 were due to the effects of MBSR.   
Within-group effects. Examining the within-group effects revealed that the error rates of the ES 
group did not differ over time (all p>0.90). Although the MBSR group did not differ between T1 and T2 
(p=0.17), MBSR participants had a lower error rate at T3 (MT3 = -0.01, SDT3 = 0.03) relative to T1 (MT1 = 
-0.10, SDT1 = 0.25; z = -2.12, n = 29, p=0.034, r=0.39), indicating improvement over time (Table 5).   
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Mediational Analysis 
For AFI total score at T2, changes on FFMQ acting with awareness subscale were identified as a 
significant mediator.  The indirect effect was 1.9544 and the 95% confidence interval ranged from .1997 
to 4.8845 indicating that relative to ES, MBSR exerted its salutary effects in part by increasing 
participants’ ability to act with awareness.  At T3, the same analytic approach revealed three significant 
mediators:  changes on FFMQ acting with awareness (indirect effect=4.1528; 95% CI [1.1309, 9.0138]), 
observing (indirect effect=2.0945, 95% CI [0.2046, 5.7429]), and nonreactivity to internal experience 
subscales (indirect effect=3.1655, 95% CI [0.5692,7.8012]).  Over the long run, MBSR seems to have 
exerted at least some of its positive effects via improving each of these mindfulness-related abilities.  
When the same analyses were conducted using Stroop accuracy instead of AFI total as the outcome 
variable, no significant mediators were identified.   
Discussion 
 To our knowledge, this is the first randomized clinical trial to test the effects of MBSR compared 
to an active control group that included both subjective and objective measures of cognitive impairment 
in cancer survivors. The exploratory findings suggest that MBSR may offer an efficacious and durable 
means to relieve CRCI, one of the most pervasive and disruptive sequelae of cancer. In terms of the 
subjective outcomes assessed by the AFI, MBSR participants experienced significant improvement over 
time on the AFI total score, as well as the Effective Action and Attentional Lapses subscales. These 
significantly exceeded improvements experienced by the ES group, often to a substantial degree as 
indicated by large to moderate effect sizes at T2 and T3. Notably, the MBSR group’s improvements were 
durable, lasting at least six months after the intervention. A similar pattern emerged with respect to the 
objective outcomes assessed by the Stroop test. Although their reaction time did not improve relative to 
ES participants, MBSR participants made significantly fewer errors at both T2 and T3, effects that were 
small to moderate in magnitude, and their accuracy rate increased over time, whereas the accuracy rate of 
ES participants did not improve. The general convergence across both types of cognitive measures 
supports the potential of MBSR as an intervention to relieve CRCI.    
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The primary aim of the parent study from which these data were drawn was to assess the effects 
of MBSR compared to ES on fatigue, with improved cognitive outcomes as a secondary aim. Notably, 
mean AFI total scores for participants in our trial were <50 for both groups at baseline, suggesting low 
cognitive functioning [43]. The MBSR group experienced significant improvements on cognitive 
outcomes at T2 and T3, and these were more robust than the effects on fatigue interference, which tended 
to favor the MBSR group only at T2 (d = -0.46, p = 0.073). These results are different than those reported 
in a recent systematic review of the effects of interventions on fatigue outcomes among cancer patients;  
decreases in mental fatigue, a construct related to CRCI, occurred less frequently and less robustly than 
reductions in other dimensions of fatigue [44]. Notably, none of the included studies in the review 
involved mindfulness-based interventions. 
To date, studies examining the effects of MBSR on cognitive outcomes among post-treatment 
cancer survivors have yielded mixed results. Three randomized trials of MBSR in cancer have included a 
patient-reported cognitive outcome; however, all of these trials used a wait-list control design. Whereas 
two of the trials reported significant effects favoring MBSR on confusion [20,25], one reported non-
significant effects on trouble remembering [45]. In contrast, the current study compared MBSR to an 
active control on attentional and executive functions and found significant and long-term effects on both 
measures. Although further research is needed, it is possible that MBSR has differential effects on 
different aspects of cognitive functioning. Although we found no significant mediators to explain the 
effects of mindfulness on an objective measure of executive functioning in our trial, mindfully acting with 
awareness, observing, and approaching internal experiences with non-reactivity mediated the effects of 
MBSR on improvement in patient-reported cognitive functioning. These results are consistent with 
research suggesting that focused attention (e.g., observing) and open monitoring (e.g., non-reactivity) are 
mechanisms of mindfulness. Cancer survivors with a mindfulness practice may be able to cope with 
common and poorly addressed symptoms (e.g., fatigue, cognitive impairment) and other survivorship 
challenges (e.g., fear of recurrence) with greater ease.              
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Several limitations of the current study should be noted.  Because this pilot investigation was 
designed to assess the impact of MBSR on fatigue and related outcomes, the findings of this secondary 
analysis on cognitive outcomes should be viewed as exploratory and warranting further study. 
Participants were enrolled on the basis of fatigue, not CRCI. Mental fatigue often co-occurs with physical 
fatigue, and in keeping with prior research, a large majority of participants reported cognitive impairment, 
as indicated by low AFI scores at baseline. In fact, the mean AFI total score of the current sample at 
baseline was approximately one standard deviation lower than the mean AFI total score reported by 
Cimprich et al. [33] in a validation sample of women newly diagnosed with early-stage breast cancer. 
Notably, the intervention effect on self-reported cognitive improvement could have been mediated by a 
variety of factors, including improved fatigue or other behavioral confounds. Further research is needed to 
determine if MBSR has similar benefits for fatigued and non-fatigued survivors with cancer-related 
cognitive impairment. Another concern is that the current sample was composed of participants with only 
two types of cancer, breast and colorectal, which limits generalizability, as does the approximately 50% 
participation rate.  However, generalizability concerns are somewhat offset by the fact that the sample 
was diverse in other ways: about 30% of participants were African-American or Hispanic, about half did 
not have a college degree, and about half reported having an income that was less than comfortable. 
Additionally, only two cognitive measures were used to avoid overtaxing fatigued cancer survivors.  
Although these measures included both subjective and objective assessments, a greater variety of methods 
would have provided better insight into the impact of MBSR on cognitive function. Finally, because we 
analyzed T2 and T3 as separate time points in an ANCOVA model, due to T2 and T3 being unique 
occasions, inflated family-wise Type I error is a limitation. Because this was a pilot study with a modest 
sample size (n=71) comparing non-invasive interventions with few side effects, we placed slightly greater 
importance on reducing Type II error over controlling family-wise Type I error and higher priority on 
using a simpler model that could handle small sample sizes rather than a more complex statistical model 
such as a mixed linear repeated measures model. 
Clinical Implications 
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Although CRCI is a potentially debilitating symptom for cancer survivors, few intervention trials 
have been conducted to address this symptom [14]. The newly released Survivorship Guidelines from the 
National Comprehensive Cancer Network (NCCN) recommend stress reduction and optimized 
management of other symptoms, including fatigue, pain, depression, and sleep disturbance, as general 
strategies to address CRCI [46]; however, no further information is provided. Findings from this study 
suggest that MBSR, with further testing, could be an efficacious and cost-effective option to address 
CRCI among cancer survivors with fatigue. MBSR participants reported high engagement in the 
intervention, as evidenced by high rates of self-reported home practice of mindfulness during the 
intervention, and the majority of participants still practiced mindfulness through the 6-month follow-up. 
Moreover, retention rates in the trial exceeded 95%, suggesting that MBSR is feasible in clinical settings.  
Conclusion 
These exploratory findings suggest MBSR may have positive effects on cognitive outcomes in 
cancer survivors with fatigue, and further investigation is warranted. Although MBSR has long been 
shown to improve well-being [20] and symptoms such as fatigue [20-22,27], depression, and anxiety [20-
23,47], few studies have examined its role with CRCI. This study provides initial evidence regarding 
MBSR’s acceptability and preliminary efficacy in addressing CRCI for cancer survivors.   
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Figure 1. CONSORT Diagram  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
Assessed for eligibility (n=224) 
Excluded (n=153) 
   Not eligible (n=79) 
   Declined to participate (n=74) 
 
      
 
Allocated to MBSR (n=35) 
 Received allocated intervention (n=32) 
 Did not receive allocated intervention (n=3) 
     Unable to attend (n=3)* 
 
Allocated to Education/Support (n=36) 
 Received allocated intervention (n=34) 
 Did not receive allocated intervention (n=2) 
     Unable to attend (n=1)* 
Patient withdrew (n=1)                                                  
Randomized (n=71) 
Assessed at T2 (n=34) 
Assessed at T3 (n=33) 
Patient withdrew (n=1) 
Lost to follow-up (n=1) 
 
Assessed at T3 (n=35) 
Assessed at T2 (n=35) 
Patient withdrew (n=1)  
Note. * Participants did not receive intervention; however, they completed all surveys as part of intent-to-treat 
analysis. 
Assessed at T1 (n=71) 
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Table 1.  Demographic and Medical Characteristics 
 
MBSR 
n=35 
ES 
n=36 
p-value 
Demographic Characteristics 
Age (y), mean (SD) 56.9 (9.9) 56.4 (12.7) 0.85 
Female, % 94.3 86.1 0.43 
White, % 77.1 63.9 0.22 
Married/partnered, % 62.9 47.2 0.19 
College degree, % 42.9 44.4 0.89 
Employed, % 51.4 52.8 0.91 
Comfortable income, % 62.9 41.7 0.07 
Medical Characteristics 
Cancer type   0.35 
        Breast cancer, % 51.7 48.3  
        Colorectal cancer, % 36.4 63.6  
Cancer stage at diagnosis, %   0.75 
        0 12.8 5.3  
        I 41.0 36.8  
        II 20.5 23.7  
        III 20.5 29.0  
Years since cancer treatment completion, 
mean (SD) 2.2 (1.4) 2.5 (1.6) 0.48 
Chemotherapy, % 65.7 80.6 0.16 
Radiation, % 80.0 75.0 0.61 
Chemo-radiation, % 45.7 55.6 0.41 
Current endocrine therapy, % 46.0 46.0 1.00 
Co-morbid medical conditions in addition to 
cancer, mean (SD) 1.8 (1.5) 1.7 (1.2) 0.75 
Symptoms and Mental Health Treatment 
Fatigue interference (FSI) 4.91 (2.17) 5.06 (1.50) 0.74 
Fatigue severity (FSI) 5.24 (1.57) 5.48 (1.30) 0.49 
Depression (PHQ-8) 11.35 (5.57) 12.53 (4.90) 0.35 
Anxiety (GAD-7)  7.46 (5.50) 8.57 (5.31) 0.39 
Sleep disturbance (ISI) 15.34 (6.45) 17.33 (6.27) 0.19 
Pain (PEG) 3.95 (3.09) 3.43 (2.80) 0.45 
Mental health treatment—current, % 17.1 22.2 0.59 
Mental health treatment—past, % 25.7 41.7 0.16 
Note. MBSR=Mindfulness-Based Stress Reduction. ES=Education/Support. SD=standard deviation. FSI=Fatigue 
Symptom Inventory (range 0-10).  PHQ-8 = 8-item Patient Health Questionnaire depression scale (range, 0-24).  
GAD-7 = 7-item Generalized Anxiety Disorder anxiety scale (range, 0-21). ISI = Insomnia Severity Index (range, 
0-28).  PEG = 3-item abbreviated version of Brief Pain Inventory (range 0-10).    
 
26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Fatigue 
Interference 
(FSI)  
Fatigue 
Severity 
(FSI) 
Depression 
(PHQ-8) 
Anxiety 
(GAD-7) 
Sleep 
Disturbance 
(ISI) 
Pain  
(PEG) AFI Total 
Fatigue Interference (FSI)  
1.00 
 
 
     
Fatigue Severity (FSI) 
0.61 
(<0.0001) 
1.00 
 
     
Depression (PHQ-8) 
0.67 
(<0.0001) 
0.41 
(0.000) 
1.00 
 
    
Anxiety (GAD-7) 
0.45 
(<0.0001) 
0.28 
(0.019) 
0.71 
(<0.0001) 
1.00 
 
   
Sleep Disturbances (ISI) 
0.41 
(0.000) 
0.31 
(0.009) 
0.53 
(<0.0001) 
0.35 
(0.003) 
1.00 
 
  
Pain (PEG) 
0.35 
(0.003) 
0.38 
(0.001) 
0.32 
(0.007) 
0.26 
(0.023) 
0.17 
(0.16) 
1.00 
 
 
AFI Total 
-0.40 
(0.001) 
-0.36 
(0.002) 
-0.54 
(<0.0001) 
-0.55 
(<0.0001) 
-0.33 
(0.005) 
0.05 
(0.70) 
1.00 
 
Table 2. Pearson Correlation Coefficients (p-values) at T1 
                 xiety 
                    ndex. 
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Dependent Variables MBSR n=351 
ES 
n=362 Diff SE diff p-value 
Pooled 
SD 
Effect 
Size (d)  
95% CI Effect 
Size 
Baseline (T1)         
AFI Total (α=0.87) 48.00 45.83 1.73 3.84 0.65 15.59 0.11 -0.37, 0.59 
Effective Action (α=0.83) 44.88 43.05 1.86 4.23 0.66 17.17 0.11 -0.37, 0.59 
Attentional Lapses (α=0.64) 51.71 47.27 3.61 4.65 0.44 18.96 0.19 -0.29, 0.67 
Interpersonal Effectiveness (α=0.78) 51.56 51.17 -0.72 5.73 0.90 22.86 -0.03 -0.52, 0.46 
Post-Intervention (T2)         
AFI Total (α=0.88) 64.64 52.28 12.57 3.54 0.001 15.15 0.83 0.37, 1.29 
Effective Action (α=0.86) 63.16 50.09 12.84 4.28 0.004 17.78 0.72 0.25, 1.19 
Attentional Lapses (α=0.80) 67.30 50.20 17.99 4.76 <0.001 20.07 0.90 0.43, 1.36 
Interpersonal Effectiveness (α=0.78) 65.54 59.50 6.99 4.26 0.106 21.02 0.33 -0.06, 0.73 
6-Month Follow-Up (T3)         
AFI Total (α=0.90) 64.83 55.21 8.90 3.75 0.021 16.16 0.55 0.10, 1.01 
Effective Action (α=0.88) 62.74 52.53 10.45 4.61 0.027 18.84 0.55 0.08, 1.03 
Attentional Lapses (α=0.80) 68.13 55.68 11.84 4.82 0.017 19.98 0.59 0.12, 1.07 
Interpersonal Effectiveness (α=0.75) 66.37 61.24 3.47 4.40 0.433 19.44 0.18 -0.26, 0.62 
Table 3. Between-Group Analysis for Attentional Function Index Total Score and Subscales 
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Note. 1Sample size for MBSR group was 35 at baseline, 34 post-intervention, and 33 at 6 months post-intervention. 2Sample size 
for Education/Support was 36 at baseline, 35 post-intervention, and 35 at 6 months post-intervention. Abbreviations:  
MBSR=Mindfulness-Based Stress Reduction. ES=Education/Support. AFI=Attentional Function Index (range 0-100). 
SE=standard error. SD=standard deviation. ES=Cohen’s d effect size. CI=confidence interval. α=Cronbach’s alpha.  
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Note. 1Sample size for MBSR group was 35 at baseline, 34 post-intervention, and 33 at 6 months post-intervention. 2Sample size for 
Education/Support was 36 at baseline, 35 post-intervention, and 35 at 6 months post-intervention. Abbreviations: MBSR=Mindfulness-Based Stress 
Reduction. ES=Education/Support. Attentional Function Index (range 0-100). SD=standard deviation. SRM=standardized response mean. 
CI=confidence interval.  T1=baseline. T2=immediately post intervention. T3=6-months post intervention.   
 
 
 
 
 MBSR n=351 
ES 
n=362 
 Mean (SD) p-value SRM (95% CI) Mean (SD) p-value SRM (95% CI) 
AFI Total           
T1 48.00 17.09    45.83 13.99    
T2 64.64 15.39 <0.0001 0.93 (0.58,1.28) 52.28 14.90 0.0227 0.40 (0.06, 0.75) 
T3 64.83 14.48 <0.0001 0.87 (0.51, 1.22) 55.21 17.59 0.0015 0.58 (0.24, 0.93) 
Effective Action           
T1 44.88 18.70    43.05 15.54    
T2 63.16 17.57 <0.0001 0.96 (0.61, 1.31) 50.09 17.98 0.0578 0.33 (-0.01, 0.68) 
T3 62.74 17.42 <0.0001 0.82 (0.46, 1.17) 52.53 20.09 0.0171 0.42 (0.08, 0.77) 
Attentional Lapses           
T1 51.71 19.61    47.27 18.30    
T2 67.30 19.09 0.0004 0.68 (0.33, 1.03) 50.20 20.98 0.3762 0.15 (-0.19, 0.50) 
T3 68.13 17.77 0.0018 0.59 (0.24, 0.95) 55.68 21.85 0.0067 0.49 (0.14, 0.83) 
Interpersonal 
Effectiveness           
T1 51.56 25.70    51.17 19.71    
T2 65.54 22.87 0.0011 0.62 (0.27, 0.96) 59.50 19.05 0.0153 0.43 (0.09, 0.78) 
T3 66.37 18.44 0.0025 0.57 (0.22, 0.93) 61.24 20.34 0.0051 0.51 (0.16, 0.85) 
Table 4. Within-Group Analysis for Attentional Function Index Total Score and Subscales 
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Table 5. Within-group and Between-Group Effects on Stroop Accuracy Rates  
 Within-group Effects1 Between-group 
Effects2 
MBSR 
n=353 
ES 
n=364 
Stroop Accuracy mean (SD) p-value r mean (SD) p-value r p-value r 
T1 -0.10 0.25   -0.08 0.19   0.990 0.002 
T2 -0.02 0.05 0.171 0.25 -0.11 0.24 0.914 0.020 0.005 0.340 
T3 -0.01 0.03 0.034 0.39 -0.07 0.19 0.986 0.003 0.030 0.280 
 
Note. 1Wilcoxon Signed Rank Test used for within-group effects. 2Wilcoxon Rank Sum Test used for 
between-group tests.   3Sample size for MBSR group was 33 at baseline, 32 post-intervention, and 30 at 6 
months post-intervention. 4Sample size for Education/Support was 36 at baseline, 33 post-intervention, 
and 30 at 6 months post-intervention. Abbreviations: MBSR=Mindfulness-Based Stress Reduction. 
ES=Education/Support. SD=standard deviation. r=effect size for Wilcoxon tests. T1=baseline. 
T2=immediately post-intervention. T3=6-months post-intervention. 
 
 
 
 
